A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

NCT00203073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: glatiramer acetate 20 mg
DRUG: glatiramer acetate 20 mg, with mitoxantrone

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.